Additionally, we propose that the main enzymes in the glycolysis pathway (MCT4, PKM2, and HK3) may function together by modulating TIME and enhancing the efficiency of anticancer immunotherapy in invasive BC, especially in HER2-enriched BC and TNBC. This evidence concerns the gene SLC16A3 and breast cancer.